This handout is for late-presenter stemi (>12 h after symptom onset). Your care team identified this based on: ischemic chest pain with onset >12 h ago + persistent st elevation.
Other reasons your team may use this plan: persistent st elevation + evolving q waves on ecg (late stemi); delayed presentation (>12 h) with ongoing chest pain or hemodynamic instability — reperfusion still indicated.
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| aspirin | 162-325 mg chewed | PO | load + 81 mg daily indefinitely | AHA 2025 ACS Class I — secondary prevention regardless of reperfusion decision |
| ticagrelor | 180 mg load → 90 mg BID | PO | BID × 12 mo if PCI performed | PLATO PMID 19717846; only if PCI performed |
| clopidogrel | 300 mg load → 75 mg daily | PO | daily × 12 mo if no PCI but late STEMI with persistent ECG changes | OMT-only late STEMI: ASA + clopidogrel for secondary prevention per ACC/AHA 2025 |
| atorvastatin | 80 mg | PO | daily indefinitely | PROVE-IT PMID 15007110; high-intensity statin regardless of reperfusion |
| carvedilol | 3.125 mg BID titrate | PO | BID | CAPRICORN PMID 11356436 — post-MI BB benefit independent of reperfusion |
| warfarin | 5 mg daily; INR 2-3 × 3 mo | PO | daily | Late presenters have higher LV thrombus / aneurysm rate; AHA 2022 Class IIa 3-mo AC |
| tenecteplase | half-dose if age ≥75 (STREAM-2); standard weight-based otherwise | IV | single bolus | STREAM-2 (Armstrong 2020) — half-dose TNK in elderly; only when PCI not feasible AND ongoing ischemia |
Plan: Late-presenter STEMI temporal phenotype — adds to parent cardio.stemi.core.v1 regimen if reperfusion indicated; otherwise OMT-only with secondary prevention bundle
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Cardiology + EP follow-up; heart pumping strength (LVEF) re-echo at 40-90 d for ICD eligibility (MADIT-II EF ≤30); cardiac rehab; secondary prevention bundle maintenance
Guideline: 2025 ACC/AHA ACS Guideline + ESC 2023 ACS + OAT trial framework for late presenters